Other
Neoplasm by Morphology
CI-CAN-00000002Explore in graph →
Non-malignant13,325 active trials222 approved drugs2,774 evidence items
- NCIt
- C4741
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000002Explore in graph →
Clinical trials
52,671 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07132684 | Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients | recruiting | Phase 3 | 240 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | recruiting | Phase 3 | 550 | Shanghai Henlius BiotechINDUSTRY | 17 | Feb 27, 2026 |
| clinicaltrials |
| NCT07441291 | CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT | recruiting | Phase 3 | 70 | Peking University People's HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT03016819 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)(APROMISS) | recruiting | Phase 3 | 325 | Advenchen Laboratories, LLCINDUSTRY | 5 | Feb 25, 2026 | clinicaltrials |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | recruiting | Phase 3 | 540 | Immunocore LtdINDUSTRY | 12 | Feb 25, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer | recruiting | Phase 3 | 540 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.INDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT06650579 | REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac Trial | recruiting | Phase 3 | 72 | Emory UniversityOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07414758 | Golidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy(T-START-M1) | recruiting | Phase 3 | 68 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05991388 | A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma(Glo-BNHL) | recruiting | Phase 2 / Phase 3 | 210 | University of BirminghamOTHER | 7 | Feb 20, 2026 | clinicaltrials |
| NCT06513065 | Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)(HIPEC-PMP) | recruiting | Phase 3 | 176 | University of SouthamptonOTHER | 1 | Feb 19, 2026 | clinicaltrials |
| NCT07417397 | Adjuvant TACE in HCC With High-risk Recurrence Factors | recruiting | Phase 3 | 442 | Guangxi Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07029217 | A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas | recruiting | Phase 3 | 375 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07413809 | Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen | recruiting | Phase 3 | 92 | The Affiliated People's Hospital of Ningbo UniversityOTHER_GOV | 1 | Feb 17, 2026 | clinicaltrials |
| NCT06937905 | Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)(TARLANEC) | recruiting | Phase 3 | 129 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402876 | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma | recruiting | Phase 3 | 20 | Aldeyra Therapeutics, Inc.INDUSTRY | 1 | Feb 11, 2026 | clinicaltrials |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | recruiting | Phase 3 | 550 | Jazz PharmaceuticalsINDUSTRY | 15 | Feb 10, 2026 | clinicaltrials |
| NCT06860269 | A 3-cohort Randomized Study Evaluating the Role of New Immunotherapeutic Agents and of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Frontline Therapy of Adults With Acute Lymphoblastic Leukemia(GRAALL-2024) | recruiting | Phase 2 / Phase 3 | 1,200 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07377578 | A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma | recruiting | Phase 3 | 394 | Guangzhou Lupeng Pharmaceutical Company LTD.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07389616 | A Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma | recruiting | Phase 2 / Phase 3 | 40 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05331521 | A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).(ImproveCodel) | recruiting | Phase 3 | 406 | University Hospital HeidelbergOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06904170 | Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma(ALICE) | recruiting | Phase 2 / Phase 3 | 196 | UNICANCEROTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07383246 | CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC(CAST-MTC) | recruiting | Phase 3 | 150 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06671548 | Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids | recruiting | Phase 3 | 120 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT06861088 | The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer(CATIQ P3) | recruiting | Phase 3 | 480 | Quercis Pharma AGINDUSTRY | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07381972 | Photodynamic Therapy Associated With Sonodynamic Therapy for the Treatment of Nodular Basal Cell Carcinoma | recruiting | Phase 3 | 142 | University of Sao PauloOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04339218 | Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma(CRYOMUNE) | recruiting | Phase 3 | 214 | Institut BergoniéOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT05843877 | Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula(XandTX) | recruiting | Phase 3 | 32 | Technische Universität DresdenOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT04702581 | A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery(POLO) | recruiting | Phase 3 | 280 | Hospices Civils de LyonOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07297329 | A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant | recruiting | Phase 3 | 292 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 29, 2026 | clinicaltrials |
| NCT07371611 | Sintilimab Plus Chemotherapy as Neoadjuvant and Adjuvant Treatment for Locally Advanced Oral Squamous Cell Carcinoma | recruiting | Phase 3 | 104 | Qunxing Li,MDOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07372300 | Modulated Electro-Hyperthermia in Combination With Multimodal Therapy for Locally Advanced Rectal Cancer(mEHT) | recruiting | Phase 3 | 126 | Shih-Kai HungOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07366801 | Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies | recruiting | Phase 2 / Phase 3 | 64 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07362459 | A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer. | recruiting | Phase 3 | 246 | Sinocelltech Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06830889 | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy | recruiting | Phase 3 | 1,450 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 22, 2026 | clinicaltrials |
| NCT05909332 | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) | recruiting | Phase 3 | 764 | Fudan UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT06957886 | A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-low Recurrent/Metastatic Breast Cancer | recruiting | Phase 3 | 566 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07221734 | Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | recruiting | Phase 3 | 632 | mAbxience Research S.L.INDUSTRY | 2 | Jan 21, 2026 | clinicaltrials |
| NCT07246590 | Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)(COVE-2) | recruiting | Phase 3 | 300 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05262010 | A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years | recruiting | Phase 3 | 13,500 | National Vaccine and Serum Institute, ChinaINDUSTRY | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06726421 | Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)(STROKER) | recruiting | Phase 3 | 252 | Sun Yat-sen UniversityOTHER | 1 | Jan 15, 2026 | clinicaltrials |
| NCT07340515 | Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III Trial | recruiting | Phase 3 | 300 | Man HuOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05006482 | Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial(GEM-S) | recruiting | Phase 3 | 668 | University of RochesterOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT06908304 | A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC | recruiting | Phase 3 | 300 | Maia BiotechnologyINDUSTRY | 4 | Jan 12, 2026 | clinicaltrials |
| NCT05669820 | Antisecretory Factor Glioblastoma Phase 2(AFGB2) | recruiting | Phase 2 / Phase 3 | 300 | Peter SiesjöOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT07328854 | 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma | recruiting | Phase 3 | 346 | Ming-Yuan ChenOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04448184 | Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)(PATH) | recruiting | Phase 3 | 662 | Ottawa Hospital Research InstituteOTHER | 1 | Jan 8, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Mar 2, 2026source: clinicaltrials